Redx pleased with progress in busy first half

Redx pleased with progress in busy first half

Redx Pharma Plc said it was “pleased with progress” as it posted its first half-year figures since listing on AIM.

Seneca EIS portfolio company Redx which raised £15m in March, increased its interim loss from £2m to £3.3m on revenue of £5.5m (£5.2m in 2014.)

Redx is working in three main areas – oncology, immunology and anti-infectives.

Chief executive Dr Neil Murray said: “There are no great surprises in these results. We are pleased with the progress we have made since the IPO and how the pipline is developing. I remain very optimistic about the opportunities available to us and Redx’s admission to AIM and share placing at the end of March will help to support our ambitious plans for our ongoing development.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.